eli lilly retatrutide clinical trials and Company's triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C Lilly's triple agonist, retatrutide, delivered

There were no group differences in circulating plasma concentrations of MPO ( p = 0.887), MMP-9 ( p = 0.345), or TIMP-1 ( p = 0.881)

95% CI 0.781.17

Key Takeaways: Patients with T2D on a GLP-1 and MDI often struggle to meet goals , but they are often overlooked for candidacy for AID The SECURE-T2D pivotal trial demonstrated improvements in glycemia across diverse racial, ethnic, and socioeconomic backgrounds, and among individuals using noninsulin glucose-lowering medications such as GLP-1s Patients with T2D on a GLP-1 can be successful on Omnipod 5

High Dose Accuracy GLP-1 drugs require precise dosing increments

The injection can be administered at any time of day, with or without meals, but maintaining a consistent day each week optimizes adherence

Patients who try to skip dose levels or accelerate their titration face significantly higher rates of nausea, vomiting, and treatment discontinuation